Tablet formulation for CGRP active compounds

A tablet comprising:

• (a) an extrudate comprising:
• (i) a polymer matrix which is a water soluble polyvinylpyrrolidone/vinyl acetate copolymer;
• (ii) a dispersing agent;
• and
• (iii) a compound of Formula I, or a pharmaceutically acceptable salt thereof:
• wherein “IV” is independently —H or —F, and wherein the dispersing agent and compound of Formula I is dispersed within said polymer matrix;
• and
• (b) a disintegration system comprising powdered sodium chloride and croscarmellose sodium.

A formulation suitable for pressing into a tablet, said formulation comprising:

• a) an extrudate composition comprising a water-soluble polyvinylpyrrolidone/vinyl acetate copolymer (PVP-VA copolymer) matrix and dispersed therein:
• (i) a compound of Formula Ia, or a pharmaceutically acceptable salt thereof:
• wherein all of Rb are either —H or all of Rb are —F;
• and
• and
• (ii) tocopherol polyethylene glycol succinate (TPGS),
• wherein said compound of Formula Ia comprises from about 5 wt % to about 23 wt % of said extrudate and TPGS comprises at least about 5 wt % of said extrudate;
• and
• b) a disintegration system comprising:
• (i) croscarmellose sodium;
• and (ii) powdered sodium chloride, wherein said disintegration system comprises about 20 wt % of said formulation.